Prenatal Screening for and Prevalence of Hepatitis B Surface Antigen in Pregnant Women and Prevention of Transmission to Infants Born to Infected Mothers-Guam, 2014
Overview
Pediatrics
Authors
Affiliations
Background: Perinatal transmission is the major mode of hepatitis B virus (HBV) transmission and drives HBV endemicity in the US territory of Guam. We assessed correlates of prenatal hepatitis B surface antigen (HBsAg) screening and HBsAg positivity among pregnant women and evaluated the care of infants of HBsAg-positive women.
Methods: Demographic and clinical data were abstracted from the maternal medical records of 966 randomly selected live infants born in 2014. Frequencies were calculated, and prevalence ratios (PRs) and 95% confidence intervals (CIs) were estimated using Poisson regression.
Results: Among the mothers of the 966 infants, 78.2% were Pacific Islanders, 56.9% were >25 years old (born before universal infant hepatitis B vaccination in Guam), 89.0% received prenatal care (PNC), 96.7% underwent prenatal HBsAg screening, and 2.0% were HBsAg positive. Approximately 15% of the women who did not have PNC were not screened for HBsAg. Receipt of PNC was associated with HBsAg screening (adjusted PR, 1.13 [95% CI, 1.04-1.23]), and HBsAg positivity was associated with a maternal age of >25 years (adjusted PR, 6.80 [95% CI, 1.32-35.08]). All 18 infants of the HBsAg-positive mothers received hepatitis B vaccine, and 17 (94.4%) received hepatitis B immunoglobulin.
Conclusion: Although the prenatal HBsAg screening prevalence in this sample was high, the maternal HBsAg prevalence among women in this sample was more than 14 times and 2 times the prevalence among US-born Pacific Islander/Asian women and all women in the continental United States, respectively. Improving access to PNC, ensuring that all pregnant women in Guam (especially those born before universal hepatitis B vaccination) are screened for HBsAg, and adopting postexposure prophylaxis for infants of HBsAg-positive mothers as standard clinical practice are important for preventing perinatal HBV transmission and reducing HBV endemicity.
Bell L, van Gemert C, Allard N, Brink A, Chan P, Cowie B Lancet Reg Health West Pac. 2023; 35:100740.
PMID: 37424691 PMC: 10326693. DOI: 10.1016/j.lanwpc.2023.100740.
Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023.
Conners E, Panagiotakopoulos L, Hofmeister M, Spradling P, Hagan L, Harris A MMWR Recomm Rep. 2023; 72(1):1-25.
PMID: 36893044 PMC: 9997714. DOI: 10.15585/mmwr.rr7201a1.
Kassaw B, Abera N, Legesse T, Workineh A, Ambaw G SAGE Open Med. 2022; 10:20503121221140778.
PMID: 36505974 PMC: 9730001. DOI: 10.1177/20503121221140778.
Suss R, Mahoney M, Arslanian K, Nyhan K, Hawley N PLoS One. 2022; 17(1):e0262010.
PMID: 35041684 PMC: 8765672. DOI: 10.1371/journal.pone.0262010.
Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission.
Ren C, Wang L, Sun W, Ma L, Dong Z, Hao A Medicine (Baltimore). 2020; 99(24):e20583.
PMID: 32541488 PMC: 7302680. DOI: 10.1097/MD.0000000000020583.